Nephrology | Rheumatology | Blood Purification, Academic Teaching Hospital Braunschweig, Braunschweig, Lower Saxony, Germany.
Microbial Proteomics, Helmholtz Centre for Infection Research, Braunschweig, Lower Saxony, Germany.
BMJ Case Rep. 2020 Aug 24;13(8):e235262. doi: 10.1136/bcr-2020-235262.
Removal of bacteria from the blood by means of extracorporeal techniques has been attempted for decades. In late 2019, the European Union licensed the first ever haemoperfusion device for removal of bacteria from the blood. The active ingredient of Seraph 100 Microbind Affinity Blood Filter is ultrahigh molecular weight polyethylene beads with endpoint-attached heparin. Bacteria have been shown to bind to heparin as they would usually do to the heparan sulfate on the cell surface, thereby being removed from the blood stream. We describe the first case of a female chronic haemodialysis patient in which this device was clinically used for a infection that persisted for 4 days despite antibiotic therapy. After a single treatment, the bacterial load decreased and the blood cultures at the end of a 4 hour haemoperfusion exhibited no bacterial growth.
几十年来,人们一直试图通过体外技术从血液中清除细菌。2019 年末,欧盟批准了首个用于从血液中清除细菌的血液灌流设备。Seraph 100 Microbind Affinity Blood Filter 的有效成分是超高相对分子质量聚乙烯珠,其末端附着有肝素。研究表明,细菌会像通常与细胞表面的硫酸乙酰肝素结合一样与肝素结合,从而从血流中被清除。我们描述了首例女性慢性血液透析患者的病例,在该患者中,尽管进行了抗生素治疗,但该设备仍在持续 4 天的感染中得到了临床应用。单次治疗后,细菌载量下降,4 小时血液灌流结束时的血培养未显示细菌生长。